Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab, Bortezomib and Lenalidomide (Linvo-VR) +/- ASCT vs DVRd in Newly Diagnosed Multiple Myeloma
NCT07428369Phase 3Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- May 2038
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 3 trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Planned start Jun 2026; status: withdrawn.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07428369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428369.